LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Listă Acțiuni・Roivant Sciences Ltd

Roivant Sciences Ltd

Închisă

SectorSănătate

28.59 -3.15

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

28.59

Maxim

29.6

Indicatori cheie
By Trading Economics
Venit	669M 356M
Vânzări	521K 2.5M
Marjă de profit	14,116.825
Angajați	721
EBITDA	-65M -354M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+27.28% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	32M 20B
Deschiderea anterioară	31.74
Închiderea anterioară	28.59

Sentimentul știrilor

By Acuity

24%

76%

56 / 344 Clasament în Healthcare

Roivant Sciences Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iun. 2026, 19:20 UTC

Principalele dinamici ale pieței

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 iun. 2026, 21:27 UTC

Câștiguri

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 iun. 2026, 20:19 UTC

Achiziții, Fuziuni, Preluări

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 iun. 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 iun. 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 iun. 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 iun. 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 iun. 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 iun. 2026, 18:33 UTC

Achiziții, Fuziuni, Preluări

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 iun. 2026, 17:50 UTC

Câștiguri

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 iun. 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 iun. 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 15:44 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 iun. 2026, 15:25 UTC

Câștiguri

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 iun. 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 iun. 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 iun. 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 iun. 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparație

Modificare preț

Roivant Sciences Ltd Așteptări

Obiectiv de preț

By TipRanks

27.28% sus

Prognoză pe 12 luni

Medie 36.53 USD 27.28%

Maxim 42 USD

Minim 29.29 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRoivant Sciences Ltd - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Roivant Sciences Ltd - Dist în ultimele 3 luni.

Sentiment

By Acuity

56 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.